Kiran Gupta

Kiran Gupta

Auto-generated profile, based on publicly available information

Kiran Gupta

Health Economics and Outcomes Research, Bristol-Myers Squibb, Plainsboro, NJ, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2015 in Journal of Hospital Medicine
Verified
Journal Article
Closed access
PDF file
KGKiran Gupta
Kiran Gupta
SMStephanie K. Mueller
Stephanie K. Mueller

31 January 2017 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
SDSteve Deitelzweig
Steve Deitelzweig
MEMichael Evans
Michael Evans
JTJeffrey Trocio
Jeffrey Trocio
KGKiran Gupta
Kiran Gupta
MLMelissa Lingohr-Smith
Melissa Lingohr-Smith
JLJay Lin
Jay Lin
Warfarin is a recommended therapy to reduce the risk of stroke in patients with nonvalvular atrial fibrillation (NVAF). The objectives of this study were to identify potential factors associated with warfarin persistence and evaluate the impact of warfarin persistence on health-care resource utilization and costs among patients with NVAF in the United States. Patients (≥18 years) with ≥1 inpatient or ≥2 outpatient diagnoses of AF without valvular disease were identified from an electronic medical record database (January 1, 2004, to January 31, 2015). The patients with NVAF were grouped into 2 cohorts—persistent with warfarin therapy and not persistent (warfarin discontinuation in <365 days). A multivariable regression was used to identify potential predictors of warfarin persistence. Health-care costs were evaluated during a 12-month follow-up period for study cohorts. Among the study population, 52%, (n = 4086) were persistent with warfarin therapy and 48% (n = 3722) were not. Patients with NVAF with higher Charlson comorbidity index and CHADS2 scores versus those with scores of 0 were more likely to demonstrate persistence with warfarin therapy. After adjusting for patient characteristics, patients with NVAF persistent with warfarin therapy versus those who were not were 30% less likely to be hospitalized during the follow-up period ( P < .001). Additionally, total all-cause health-care costs (US $2183, P < .001) and stroke-related costs (US $788, P < .001) were significantly lower among patients persistent with warfarin therapy versus those who were not. Patients with NVAF who have greater comorbidity and stroke risk are more likely to be persistent with warfarin therapy. Patients with NVAF who are persistent with warfarin therapy versus those who are not have lower all-cause and stroke-related health-care costs.

1 March 2015 in Acta Astronautica
Verified
Journal Article
Closed access
CWC. Roger White
C. Roger White
TYTao Yu
Tao Yu
KGKiran Gupta
Kiran Gupta
SBStephen K. Babitz
Stephen K. Babitz
LBLeland L. Black
Leland L. Black
DKDennis F. Kucik
Dennis F. Kucik

31 January 2023 in International Journal of Advanced Research
Verified
Journal Article
Open access
SNSumit Deb Nath
Sumit Deb Nath
KGKiran Gupta
Kiran Gupta
RSRahul Sharma
Rahul Sharma
SSSaqib Siddique
Saqib Siddique
Introduction: More than half of reproductive difficulties cannot be attributed to female characteristics. A number of illnesses and conditions that may have an impact on male fertility have been found via recent research. A number of underlying diseases and health issues, as well as environmental variables, may contribute to male infertility. For a sexually active couple, infertility is diagnosed after a year of unsuccessful attempting to conceive. Infertility affects around 19% of couples who have trouble conceiving. Any and all racial and ethnic groups may feel at home within these parameters. Materials and Methods: The study was conducted in 100 infertile patients and 50 fertile subjects were use as controls. The sample will be obtained by masturbation and ejaculated into a clean and proper labeled, wide-mouthed container made of glass or plastic according to the rules laid down by WHO. Result and Conclusion: The sperm count in infertile and fertile subjects were 15.8 ± 2.85 and 56.57 ± 8.47 respectively, Motility 37.6±1.8and 54.4 ±1.8, volume 2±0.8 and 2.6±0.1, viability 53.7±1.4 and 66±1.2. Out of 100 infertile patients 5 percent subjects had Y chromosomal microdeletions (5 samples of 100).